Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
RayzeBio is launching with $45 million in series A funding to develop radioisotope therapies for cancer. The company makes radiopharmaceuticals using macrocyclic peptides and actinium-225 that can be used for both diagnostic imaging and treatment by switching out the isotope. The company says a clinician can see a tumor’s uptake of a possible treatment before proceeding with it. RayzeBio has a partnership with PeptiDream to develop the peptides.
This article has been sent to the following recipient: